Wird geladen...
Emerging therapies for small cell lung cancer
Currently, chemotherapy remains the standard treatment for first- and second-line management of small cell lung cancer (SCLC). Immunotherapy has made progress in the treatment of SCLC, and nivolumab, pembrolizumab, atezolizumab, and durvalumab have led to significant improvements in clinical outcome...
Gespeichert in:
| Veröffentlicht in: | J Hematol Oncol |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BioMed Central
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6498593/ https://ncbi.nlm.nih.gov/pubmed/31046803 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-019-0736-3 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|